Daré Bioscience is set to launch DARE to PLAY™ Sildenafil Cream, the first evidence-backed topical treatment for female sexual arousal, in late 2025. Partnering with Rosy Wellness, the company has begun an awareness campaign to reduce stigma and provide women with trusted education and support around sexual health. A Major Step Forward in Women’s Health In a field often overlooked by medical innovation, Daré Bioscience, Inc...
Cancer drugs remain among the most expensive medicines in healthcare. While innovative treatments bring hope, their high cost often restricts access for patients and strains health budgets. Generic oncology drugs, both small-molecule generics and biosimilar,s have emerged as the most powerful tool to improve affordability...
Zug, Switzerland (June 26, 2025) – Galderma has announced two new Phase II clinical trials to study nemolizumab, a drug designed to block the IL-31 receptor. These trials will focus on patients with Systemic Sclerosis (SSc) and Chronic Pruritus of Unknown Origin (CPUO), two conditions with high unmet medical needs and no approved treatments available. What is Nemolizumab? Nemolizumab is a monoclonal antibody...
Roche announced significant progress in its Alzheimer’s disease research portfolio during the Alzheimer’s Association International Conference (AAIC) 2025 in Toronto. The company presented detailed results from its investigational therapy trontinemab and showcased its Elecsys pTau217 blood test, both of which aim to transform the detection and treatment of Alzheimer’s disease. Advancing trontinemab with Brainshuttle technology Roche’s investigational therapy trontinemab is a bispecific monoclonal antibody developed using the company’s proprietary Brainshuttle technology...
Cipla Limited has taken significant strides in its respiratory segment with the planned FY26 launch of its generic version of GlaxoSmithKline’s blockbuster asthma and COPD drug, Advair Diskus®, in the United States. The move follows the successful completion of Phase-3 clinical trials and the filing of an Abbreviated New Drug Application (ANDA) with the US Food and Drug Administration (USFDA). The Advair Opportunity: A Multi-Billion Dollar Market Understanding the Market Landscape Advair Diskus, GlaxoSmithKline's blockbuster respiratory medication, represents one of the most lucrative opportunities in the generic pharmaceutical space...
The global vaccine market is changing faster than ever, but many businesses, researchers, and policymakers struggle to keep up with the latest shifts. Ignoring these changes can mean missed opportunities in investment, technology adoption, and public health preparedness. Falling behind could also leave gaps in vaccine access, innovation, and disease prevention...
Patient segmentation in cardiology helps hospitals and clinics group patients based on health risks, behavior, and outcomes. This allows care teams to provide better, faster, and more personalized treatment. With the rise of chronic heart diseases and growing data from EHRs and diagnostic tools, segmentation is now more important than ever...
WAYNE, Pa. (June 2, 2025) — Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing treatments for immuno-inflammatory diseases, has announced the initiation of a Phase 2 clinical trial of its leading drug candidate, bosakitug (ATI-045)...
Lund, Sweden - April 25, 2025: Camurus has announced a major regulatory milestone as the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion for Oczyesa (CAM2029). This once-monthly treatment is designed for adult patients living with acromegaly, a rare hormonal disorder. The recommendation is based on strong results from seven clinical trials, including two pivotal Phase 3 studies...
Intuitive’s da Vinci 5 Surgical Robot Approved for Use in Europe Sunnyvale, California, July 2025 — Intuitive, a global leader in robotic-assisted surgery, has announced that its latest surgical robot, the da Vinci 5 Surgical System, has received CE Mark approval. This approval allows the use of the da Vinci 5 system for both adult and pediatric patients across Europe in a wide range of minimally invasive surgeries, including urologic, gynecologic, and general laparoscopic procedures. This regulatory milestone follows the U.S...
Waltham, Massachusetts, July 28, 2025 — The United States Food and Drug Administration has officially approved Empaveli, also known as pegcetacoplan. This innovative treatment was developed by Apellis Pharmaceuticals. It is now the first approved therapy for two rare and serious kidney diseases...
As a real estate investor or market analyst, one of your biggest challenges is identifying undervalued properties before the rest of the market catches on. This becomes even harder in emerging markets, where data is often incomplete, pricing trends are inconsistent, and local insights are difficult to validate. Yet, these markets also offer some of the highest potential returns if approached with the right tools and strategy...
August 2, 2025 | Thousand Oaks, CA — Amgen has officially announced Meritide (formerly MariTide, maridebart cafraglutide), its groundbreaking investigational therapy for obesity, type 2 diabetes, and related cardiometabolic conditions, marking a bold step forward in the global fight against metabolic disease. A breakthrough in obesity and diabetes management In results from its Phase 2 clinical trial, Meritide showed strong and steady weight loss in adults living with obesity, both with and without type 2 diabetes. People with obesity but no diabetes lost an average of up to 20 percent of their body weight...
Label expansion in the pharmaceutical and life sciences industry refers to the process of gaining regulatory approval to use an existing drug for new indications, patient groups, or treatment settings. It’s a critical growth path for companies aiming to maximize the value of approved therapies. As an organization evaluating label expansion opportunities, you need more than just clinical trial data...
Eli Lilly has officially acquired Verve Therapeutics, a pioneering biotech company specializing in in vivo gene editing for cardiovascular disease. The deal, announced on July 25, 2025, is valued at up to $1.3 billion. It includes an upfront cash payment of $10.50 per share and a contingent value right (CVR) that may provide an additional $3.00 per share if Verve’s lead candidate reaches a U.S...
On July 22, 2025, Sanofi announced a definitive agreement to acquire Vicebio, a clinical-stage biotechnology company developing next-generation respiratory vaccines. The deal is valued at $1.6 billion and includes a $1.15 billion upfront payment with up to $450 million in milestone-based payments. The acquisition aims to expand Sanofi’s respiratory vaccine portfolio through access to Vicebio’s proprietary Molecular Clamp technology...
Clinical development is a long and expensive process. It often takes years of planning, testing, and data collection to bring a new medicine to market. Even then, most clinical trials do not succeed...
Clinical trials help test if new medicines are safe and effective. But many trials fail to find enough people or keep them until the end. One reason is that trial designs often do not match what patients need or want...
Generative AI is transforming the way pharmaceutical companies operate. It helps teams discover drugs faster, write documents quicker, and find insights in huge amounts of data. Instead of doing everything manually, experts can now use GenAI to save time and focus on what matters most—patient care and innovation...
Summary: Roche, one of the world’s biggest drugmakers, is thinking about selling its medicines directly to patients in the United States. The company’s CEO, Thomas Schinecker, said this plan could help reduce the high cost of prescription drugs in the country. Roche is already talking with the U.S...
